Takeda’s zasocitinib (TAK-279) beat Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout for moderate to severe plaque psoriasis. The result moves Takeda’s oral TYK2 inhibitor into direct competitive positioning within a crowded TYK2 inhibitor landscape, where efficacy and safety profiles are closely compared. Zasocitinib was acquired through Takeda’s 2022 deal tied to Nimbus Therapeutics’s wholly owned subsidiary. The phase III update adds momentum for Takeda’s registration plans and raises the stakes for head-to-head interpretation versus existing TYK2 standards. If confirmed in full trial materials, the comparative signal could shape prescribing preferences for biologic-naïve and previously treated psoriasis populations.